Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1565

1.

Natalizumab and monocytes in multiple sclerosis: The dim haze of mystery and the enchantment of pursuit.

Deason K, Miller-Little WA, Stüve O.

Mult Scler. 2015 May 26. pii: 1352458515574150. [Epub ahead of print] No abstract available.

PMID:
26014603
2.

Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.

Van Tassel SH, Gupta MP, Orlin A, Nealon NM, Patel SS.

Neurology. 2015 May 26;84(21):2198-9. doi: 10.1212/WNL.0000000000001611. No abstract available.

PMID:
26009560
3.

Risk tolerance to MS therapies: Survey results from the NARCOMS registry.

Fox RJ, Salter A, Alster JM, Dawson NV, Kattan MW, Miller D, Ramesh S, Tyry T, Wells BW, Cutter G.

Mult Scler Relat Disord. 2015 May;4(3):241-9. doi: 10.1016/j.msard.2015.03.003. Epub 2015 Mar 26.

PMID:
26008941
4.

Prevalence of Antibodies Against JC Virus in Serum of Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.

Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A.

Clin Gastroenterol Hepatol. 2015 May 19. pii: S1542-3565(15)00698-9. doi: 10.1016/j.cgh.2015.05.022. [Epub ahead of print]

PMID:
26001336
5.

CD4 cell response to interval therapy with natalizumab.

Berkovich R, Togasaki DM, Cen SY, Steinman L.

Ann Clin Transl Neurol. 2015 May;2(5):570-4. doi: 10.1002/acn3.190. Epub 2015 Mar 6.

6.

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.

Lin YC, Winokur P, Blake A, Wu T, Romm E, Bielekova B.

Ann Clin Transl Neurol. 2015 May;2(5):445-55. doi: 10.1002/acn3.181. Epub 2015 Apr 7.

7.

Decisional Dilemmas in Discontinuing Prolonged Disease-Modifying Treatment for Multiple Sclerosis [Internet].

Butler M, Forte ML, Schwehr N, Carpenter A, Kane RL.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Apr.

8.

Natalizumab induction and maintenance therapy for Crohn's disease.

[No authors listed]

N Engl J Med. 2015 May 21;372(21):2074. doi: 10.1056/NEJMx140055. No abstract available.

9.
10.

Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.

Poulakos M, Machin JD, Pauly J, Grace Y.

J Pharm Pract. 2015 May 6. pii: 0897190015579610. [Epub ahead of print]

PMID:
25952593
11.

Progressive multifocal leukoencephalopathy: Dot-shaped inclusions and virus-host interactions.

Shishido-Hara Y.

Neuropathology. 2015 May 6. doi: 10.1111/neup.12203. [Epub ahead of print]

PMID:
25946231
12.

Induction and escalation therapies in multiple sclerosis.

Fenu G, Lorefice L, Frau F, Coghe GC, Marrosu MG, Cocco E.

Antiinflamm Antiallergy Agents Med Chem. 2015;14(1):26-34.

PMID:
25938688
13.

Acute retinal necrosis and immune reconstitution inflammatory syndrome in a natalizumab-treated patient with multiple sclerosis.

Saraiva VS.

Retin Cases Brief Rep. 2015 Summer;9(3):195-7. doi: 10.1097/ICB.0000000000000136.

PMID:
25933353
14.

Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.

Pietropaolo V, Bellizzi A, Anzivino E, Iannetta M, Zingaropoli MA, Rodio DM, Morreale M, Pontecorvo S, Francia A, Vullo V, Palamara AT, Ciardi MR.

J Neurovirol. 2015 May 1. [Epub ahead of print]

PMID:
25930159
15.

Natalizumab as a Disease-Modifying Therapy in Chronic Inflammatory Demyelinating Polyneuropathy - A Report of Three Cases.

Vallat JM, Mathis S, Ghorab K, Milor MA, Richard L, Magy L.

Eur Neurol. 2015 Apr 29;73(5-6):294-302. [Epub ahead of print]

PMID:
25925430
16.

Established disease-modifying treatments in relapsing-remitting multiple sclerosis.

Oh J, O'Connor PW.

Curr Opin Neurol. 2015 Jun;28(3):220-9. doi: 10.1097/WCO.0000000000000202.

PMID:
25923124
17.

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.

Frisell T, Forsberg L, Nordin N, Kiesel C, Alfredsson L, Askling J, Hillert J, Olsson T, Piehl F.

Mult Scler. 2015 Apr 28. pii: 1352458515579216. [Epub ahead of print]

PMID:
25921036
18.

Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.

Craddock J, Markovic-Plese S.

Expert Rev Clin Pharmacol. 2015 May;8(3):283-96. doi: 10.1586/17512433.2015.1036030.

PMID:
25916665
19.

Managing refractory Crohn's disease: challenges and solutions.

Tanida S, Ozeki K, Mizoshita T, Tsukamoto H, Katano T, Kataoka H, Kamiya T, Joh T.

Clin Exp Gastroenterol. 2015 Apr 10;8:131-40. doi: 10.2147/CEG.S61868. eCollection 2015. Review.

20.

Integrin antagonists are effective and safe for Crohn's disease: A meta-analysis.

Ge WS, Fan JG.

World J Gastroenterol. 2015 Apr 21;21(15):4744-9. doi: 10.3748/wjg.v21.i15.4744.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk